---
title: "RPC: No investment or research and development plans in the field of synthetic biology at present"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234344257.md"
description: "RPC stated on the interactive platform that the company currently has no plans for investment, research and development, or operations in the field of synthetic biology"
datetime: "2025-04-03T07:16:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234344257.md)
  - [en](https://longbridge.com/en/news/234344257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234344257.md)
generator: "portal-rs"
---

# RPC: No investment or research and development plans in the field of synthetic biology at present

RPC stated on the interactive platform that the company currently has no plans for investment, research and development, or operations in the field of synthetic biology

### Related Stocks

- [000650.CN](https://longbridge.com/en/quote/000650.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**